Trial Profile
A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Tergenpumatucel-L (Primary) ; Docetaxel; Indoximod
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lumos Pharma; NewLink Genetics Corporation
- 04 Apr 2022 Status changed from active, no longer recruiting to discontinued.
- 17 May 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2016 According to CT.gov record, phase of the trial changed from phase II to phase I/II, official title changed.Also,safety is now included as primary endpoint,treatment arms changed from 1 to 2,planned patient number changed from 59 to 115 and treatment section revised with changes in frequency of drugs administration(i.e.for Tergenpumatucel-L- frequency changed from q2w total 24 doses to q3w total 18 doses for Indoximod it changed from BID to TID).